The Journal of the American Dental Association
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Am Dent Assoc, Vol 132, No 3, 319-326.
© 2001 American Dental Association

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HATCH, J. P.
Right arrow Articles by SAUNDERS, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HATCH, J. P.
Right arrow Articles by SAUNDERS, M. J.
Related Collections
Right arrow Pharmacology

CLINICAL PRACTICE

JADA Continuing Education

Is use of exogenous estrogen associated with temporomandibular signs and symptoms?



JOHN P. HATCH, Ph.D., JOHN D. RUGH, Ph.D., SHIRO SAKAI, D.D.S., M.S. and MICHELE J. SAUNDERS, D.M.D., M.S., M.P.H.

Background. Studies of historical data suggest a link between exogenous estrogen use and referral for treatment for temporomandibular disorders, or TMDs. The purpose of the authors’ study was to determine the association between exogenous estrogen use and signs and symptoms of TMD assessed by direct physical examination in a randomly selected community sample of primarily postmenopausal women.

Methods. A calibrated clinical examiner examined a stratified random sample of 510 women aged 37 to 82 years using the Craniomandibular Index, or CMI. All medications that subjects were taking at the time of the examination were identified by interview and examination of subjects’ medication containers on two occasions. One hundred seventy-four subjects were taking medications containing estrogen, and 336 were taking no such medications.

Results. The muscle and joint signs and symptoms of women taking and not taking estrogen were not significantly different after the authors controlled for sociocultural, demographic and health care utilization variables. Estrogen use also failed to distinguish women receiving relatively high and low scores on the CMI.

Conclusion. Estrogen replacement therapy does not place women at increased risk of developing TMDs.

Clinical Implications. Clinicians need not be concerned that patients taking oral contraceptives or replacement estrogens are at increased risk of developing TMDs.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright©1995-2001 American Dental Association (ADA).
Reproduction or republication strictly prohibited without prior written permission of ADA.